100 days into HHS tenure, Alex Azar earns higher praise than Tom Price

May 9 marks 100 days since Alex Azar was sworn in as the second HHS Secretary under President Donald Trump. Judging by what lobbyists, policy experts and Democrats said to Axios, he’s seen in a more positive light than his predecessor Tom Price, MD.

The two men have similar views on certain policies, such as favoring repeal of the Affordable Care Act (ACA) and making conservative-minded reforms to Medicaid. When it comes to reforming the healthcare delivery system and moving towards value-based payments, however, they diverge, with Azar embracing such changes and Price trying to roll them back.

“Price was the guy refilling the punch bowl—the guardian of a fee-for-service system exposed as an unsuccessful and unscrupulous secretary,” said one healthcare lobbyist. “Azar is the reformer who knows the role government must play in helping transition to a better-value health care system.”

Part of the praise for Azar focused on how his priorities focus on what HHS can actually accomplish. Price’s attention was all on repealing the ACA, which was really in the hands of Congress and President Trump.

The plaudits for Azar only go so far, however, when reaching into more partisan issues. Former CMS Administrator Andy Slavitt applauded Azar for reaching out to “people who think differently than he does,” but also criticized the agency’s goals under his leadership, such as pushing for Medicaid work requirements, non-ACA-compliant insurance plans and changes to policies around birth control and reproductive health.

Read more at the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.